Literature DB >> 21561598

RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression.

Tamaki Yamada1, Masumi Tsuda, Tomomi Takahashi, Yasunori Totsuka, Masanobu Shindoh, Yusuke Ohba.   

Abstract

Recent findings have focused attention on the molecular consequences of the microenvironment in tumor progression, but events occurring in cancer cells themselves in response to their ambient conditions remain obscure. Here, we identify receptor activator of nuclear factor κB ligand (RANKL) as a microenvironment-specific factor essential for tumorigenesis in vivo, using head and neck squamous cell carcinoma (HNSCC) as a model. In human HNSCC tissues, RANKL is abundantly expressed, and its expression level correlates with the histological grade of differentiation. RANKL levels are significantly higher in poorly differentiated SCCs than in well or moderately differentiated SCCs. In contrast, all HNSCC cell lines tested displayed extremely low RANKL expression; however, RANKL is efficiently up-regulated when these cell lines are inoculated in the head and neck region of mice. RANKL expression is restored in a microenvironment-specific manner, and cannot be observed when the cells are inoculated in the hindlimbs. Forced expression of RANKL compensates for tumor growth in the hindlimb milieu, promotes epithelial mesenchymal transition, and induces tumor angiogenesis, in a manner independent of vascular endothelial growth factor (VEGF). These results implicate RANKL expression causatively in tumor growth and progression in HNSCC in vivo. RANKL may provide a novel functional marker for biological malignancy and a therapeutic target based on the specific nature of the microenvironment.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21561598      PMCID: PMC3124328          DOI: 10.1016/j.ajpath.2011.02.003

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  68 in total

Review 1.  Epithelial-mesenchymal transitions in development and pathologies.

Authors:  Jean Paul Thiery
Journal:  Curr Opin Cell Biol       Date:  2003-12       Impact factor: 8.382

Review 2.  CD44: from adhesion molecules to signalling regulators.

Authors:  Helmut Ponta; Larry Sherman; Peter A Herrlich
Journal:  Nat Rev Mol Cell Biol       Date:  2003-01       Impact factor: 94.444

3.  Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Authors:  D L Lacey; E Timms; H L Tan; M J Kelley; C R Dunstan; T Burgess; R Elliott; A Colombero; G Elliott; S Scully; H Hsu; J Sullivan; N Hawkins; E Davy; C Capparelli; A Eli; Y X Qian; S Kaufman; I Sarosi; V Shalhoub; G Senaldi; J Guo; J Delaney; W J Boyle
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

4.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

Review 5.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

6.  Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature.

Authors:  George J Klarmann; Elaine M Hurt; Lesley A Mathews; Xiaohu Zhang; Maria A Duhagon; Tashan Mistree; Suneetha B Thomas; William L Farrar
Journal:  Clin Exp Metastasis       Date:  2009-02-17       Impact factor: 5.150

Review 7.  The basics of epithelial-mesenchymal transition.

Authors:  Raghu Kalluri; Robert A Weinberg
Journal:  J Clin Invest       Date:  2009-06       Impact factor: 14.808

Review 8.  Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis.

Authors:  Josef Gotzmann; Mario Mikula; Andreas Eger; Rolf Schulte-Hermann; Roland Foisner; Hartmut Beug; Wolfgang Mikulits
Journal:  Mutat Res       Date:  2004-01       Impact factor: 2.433

Review 9.  Epigenetic targets for immune intervention in human malignancies.

Authors:  Michele Maio; Sandra Coral; Elisabetta Fratta; Maresa Altomonte; Luca Sigalotti
Journal:  Oncogene       Date:  2003-09-29       Impact factor: 9.867

10.  An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression.

Authors:  Jay S Desgrosellier; Leo A Barnes; David J Shields; Miller Huang; Steven K Lau; Nicolas Prévost; David Tarin; Sanford J Shattil; David A Cheresh
Journal:  Nat Med       Date:  2009-09-06       Impact factor: 53.440

View more
  10 in total

Review 1.  Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.

Authors:  Maria V Deligiorgi; Mihalis I Panayiotidis; John Griniatsos; Dimitrios T Trafalis
Journal:  Clin Exp Metastasis       Date:  2019-10-01       Impact factor: 5.150

Review 2.  RANKL biology.

Authors:  Noriko Takegahara; Hyunsoo Kim; Yongwon Choi
Journal:  Bone       Date:  2022-02-16       Impact factor: 4.626

3.  Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors.

Authors:  Maria M Szwarc; Ramakrishna Kommagani; Allison P Jacob; William C Dougall; Michael M Ittmann; John P Lydon
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

Review 4.  Targeting RANKL in metastasis.

Authors:  William C Dougall; Ingunn Holen; Eva González Suárez
Journal:  Bonekey Rep       Date:  2014-04-09

Review 5.  RANK-RANKL signalling in cancer.

Authors:  Nathalie Renema; Benjamin Navet; Marie-Françoise Heymann; Frédéric Lezot; Dominique Heymann
Journal:  Biosci Rep       Date:  2016-08-05       Impact factor: 3.840

6.  BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.

Authors:  Elisabet Cuyàs; Bruna Corominas-Faja; María Muñoz-San Martín; Begoña Martin-Castillo; Ruth Lupu; Joan Brunet; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Oncotarget       Date:  2017-05-23

7.  Loss of MMP-27 Predicts Mandibular Bone Invasion in Oral Squamous Cell Carcinoma.

Authors:  Jonas Eichberger; Florian Weber; Gerrit Spanier; Michael Gerken; Stephan Schreml; Daniela Schulz; Mathias Fiedler; Nils Ludwig; Richard Josef Bauer; Torsten Eugen Reichert; Tobias Ettl
Journal:  Cancers (Basel)       Date:  2022-08-22       Impact factor: 6.575

8.  Chronic inflammation in cancer development.

Authors:  Gabriele Multhoff; Michael Molls; Jürgen Radons
Journal:  Front Immunol       Date:  2012-01-12       Impact factor: 7.561

9.  Receptor activator of NF-κB ligand induces cell adhesion and integrin α2 expression via NF-κB in head and neck cancers.

Authors:  Tamaki Yamada; Masumi Tsuda; Takanori Wagatsuma; Yoichiro Fujioka; Mari Fujioka; Aya O Satoh; Kosui Horiuchi; Shinya Nishide; Asuka Nanbo; Yasunori Totsuka; Hisashi Haga; Shinya Tanaka; Masanobu Shindoh; Yusuke Ohba
Journal:  Sci Rep       Date:  2016-03-24       Impact factor: 4.379

Review 10.  RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review.

Authors:  Peter A van Dam; Yannick Verhoeven; Julie Jacobs; An Wouters; Wiebren Tjalma; Filip Lardon; Tim Van den Wyngaert; Jonatan Dewulf; Evelien Smits; Cécile Colpaert; Hans Prenen; Marc Peeters; Martin Lammens; Xuan Bich Trinh
Journal:  Int J Mol Sci       Date:  2019-05-02       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.